| Name | Title | Contact Details |
|---|
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.
Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.
At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!
ALERT Life Sciences Computing is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.